KR102820822B1 - B-raf 키나제 억제제의 결정성 염 - Google Patents

B-raf 키나제 억제제의 결정성 염 Download PDF

Info

Publication number
KR102820822B1
KR102820822B1 KR1020207014962A KR20207014962A KR102820822B1 KR 102820822 B1 KR102820822 B1 KR 102820822B1 KR 1020207014962 A KR1020207014962 A KR 1020207014962A KR 20207014962 A KR20207014962 A KR 20207014962A KR 102820822 B1 KR102820822 B1 KR 102820822B1
Authority
KR
South Korea
Prior art keywords
salt
cancer
pyridin
pyrrolo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207014962A
Other languages
English (en)
Korean (ko)
Other versions
KR20200088345A (ko
Inventor
울리케 베르트만
게르트-미카엘 마이어
보도 베트체마이어
오트마르 샤프
Original Assignee
자이노믹 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 자이노믹 파마슈티컬스 인코포레이티드 filed Critical 자이노믹 파마슈티컬스 인코포레이티드
Publication of KR20200088345A publication Critical patent/KR20200088345A/ko
Application granted granted Critical
Publication of KR102820822B1 publication Critical patent/KR102820822B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207014962A 2017-10-26 2018-10-26 B-raf 키나제 억제제의 결정성 염 Active KR102820822B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577313P 2017-10-26 2017-10-26
US62/577,313 2017-10-26
PCT/US2018/057792 WO2019084459A1 (en) 2017-10-26 2018-10-26 CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR

Publications (2)

Publication Number Publication Date
KR20200088345A KR20200088345A (ko) 2020-07-22
KR102820822B1 true KR102820822B1 (ko) 2025-06-16

Family

ID=64277870

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207014962A Active KR102820822B1 (ko) 2017-10-26 2018-10-26 B-raf 키나제 억제제의 결정성 염

Country Status (15)

Country Link
US (2) US11306086B2 (enExample)
EP (2) EP3700530B1 (enExample)
JP (2) JP7230041B2 (enExample)
KR (1) KR102820822B1 (enExample)
CN (2) CN111818924B (enExample)
AU (2) AU2018355528B2 (enExample)
BR (1) BR112020008248A2 (enExample)
CA (1) CA3080324A1 (enExample)
ES (1) ES2947411T3 (enExample)
IL (1) IL274027B2 (enExample)
MX (1) MX2020004148A (enExample)
MY (1) MY203853A (enExample)
PH (1) PH12020550485A1 (enExample)
SG (1) SG11202003635TA (enExample)
WO (1) WO2019084459A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2947411T3 (es) 2017-10-26 2023-08-08 Xynomic Pharmaceuticals Inc Sales cristalinas de un campo inhibidor de quinasa B-RAF
JP2022069426A (ja) * 2020-10-23 2022-05-11 マイラン ラボラトリーズ リミテッド テネリグリプチン２．５臭化水素酸塩のアモルファスを調製する方法
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104388A1 (en) 2011-02-02 2012-08-09 Boehringer Ingelheim International Gmbh New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
MXPA06005578A (es) * 2003-11-17 2006-08-11 Pfizer Prod Inc Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
TWI423980B (zh) * 2009-09-28 2014-01-21 Hoffmann La Roche 苯并氧氮呯ｐｉ３ｋ抑制劑化合物及使用方法
WO2013010679A1 (en) 2011-07-15 2013-01-24 Novartis Ag Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2016167340A1 (ja) 2015-04-16 2016-10-20 日東電工株式会社 Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物
CN105801584B (zh) * 2016-03-16 2019-03-05 中国药科大学 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途
ES2947411T3 (es) 2017-10-26 2023-08-08 Xynomic Pharmaceuticals Inc Sales cristalinas de un campo inhibidor de quinasa B-RAF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104388A1 (en) 2011-02-02 2012-08-09 Boehringer Ingelheim International Gmbh New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
JP2023062074A (ja) 2023-05-02
IL274027B1 (en) 2023-08-01
US20200283433A1 (en) 2020-09-10
AU2018355528A1 (en) 2020-05-07
PH12020550485A1 (en) 2021-03-22
RU2020116763A (ru) 2021-11-26
JP7230041B2 (ja) 2023-02-28
WO2019084459A1 (en) 2019-05-02
CN111818924A (zh) 2020-10-23
SG11202003635TA (en) 2020-05-28
JP2021501199A (ja) 2021-01-14
AU2018355528B2 (en) 2021-11-18
US11753409B2 (en) 2023-09-12
CN111818924B (zh) 2023-08-15
EP4245758A3 (en) 2023-12-20
EP4245758A2 (en) 2023-09-20
CN116942672A (zh) 2023-10-27
MX2020004148A (es) 2022-09-09
CA3080324A1 (en) 2019-05-02
BR112020008248A2 (pt) 2020-10-20
EP3700530B1 (en) 2023-04-19
KR20200088345A (ko) 2020-07-22
AU2022201044A1 (en) 2022-03-10
ES2947411T3 (es) 2023-08-08
AU2022201044B2 (en) 2023-07-13
MY203853A (en) 2024-07-22
RU2020116763A3 (enExample) 2022-04-29
CN116942672B (zh) 2026-04-14
IL274027B2 (en) 2023-12-01
IL274027A (en) 2020-06-30
EP3700530A1 (en) 2020-09-02
US20220204506A1 (en) 2022-06-30
US11306086B2 (en) 2022-04-19

Similar Documents

Publication Publication Date Title
AU2022201044B2 (en) Crystalline salts of a B-RAF kinase inhibitor
USRE50594E1 (en) Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
ES2739697T3 (es) Nuevos compuestos y derivados de espiro[3H-indol-3,2-pirrolidin]-2(1H)-ona como inhibidores de MDM2-p53
EP3083625B1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
WO2016001376A1 (en) New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
RU2798091C2 (ru) Кристаллические соли ингибитора b-raf-киназы
HK40098127A (en) Crystalline salts of a b-raf kinase inhibitor
HK40035621A (en) Crystalline salts of a b-raf kinase inhibitor
HK40035621B (en) Crystalline salts of a b-raf kinase inhibitor
HK1252365B (en) Spiro[3h-indole-3,2’-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200525

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211025

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231205

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240817

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250324

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250611

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250612

End annual number: 3

Start annual number: 1

PG1601 Publication of registration